Clinic
Dignity Community Care
Dignity Community Care was paid $71.07M by Medicaid between Jan 2018 and Dec 2024, across 352 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoDIGNITY COMMUNITY CARE
CHANDLER, AZ 85224
CHANDLER, AZ 85224
33aNPI1700910189assigned 03/15/2007
33bProvider typeUrgent Care Clinic/Center
28Total paid$71.07M
24GClaims1,987,328
24DCodes billed352
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Arizona
Rank by total paid#4 of 81
Median peer was paid$312K
This provider vs. median228×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 300,535 | $11.01M | |
| 2019 | 305,564 | $11.12M | |
| 2020 | 251,746 | $8.70M | |
| 2021 | 297,550 | $10.26M | |
| 2022 | 324,496 | $11.44M | |
| 2023 | 308,196 | $10.90M | |
| 2024incomplete | 199,241 | $7.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 54,235 | 49,188 | $11.52M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 33,974 | 30,634 | $10.18M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 14,675 | 13,614 | $8.56M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 40,302 | 37,713 | $6.48M |
| G0378 | Hospital observation service, per hour | 6.6% | 26,691 | 13,201 | $4.68M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.4% | 55,835 | 53,142 | $2.44M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.3% | 20,134 | 15,760 | $2.32M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.8% | 36,068 | 33,880 | $2.02M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 4,728 | 4,375 | $1.90M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.0% | 4,985 | 4,634 | $1.44M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 16,825 | 13,312 | $1.40M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.9% | 11,214 | 9,415 | $1.38M |
340 more codes
| 72125 | Computed tomography, cervical spine; without contrast material | 1.8% | 5,822 | $1.31M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.8% | 3,666 | $1.25M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 17,075 | $1.22M |
| 70498 | 1.3% | 2,352 | $904K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 15,433 | $848K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 10,254 | $675K |
| 47562 | <1% | 165 | $567K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 10,433 | $535K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 32,044 | $502K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 5,209 | $501K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 426 | $416K |
| 93458 | <1% | 324 | $394K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,324 | $346K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,839 | $335K |
| 72131 | <1% | 2,499 | $310K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,867 | $306K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 9,930 | $296K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,070 | $289K |
| 12001 | <1% | 1,506 | $267K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 11,418 | $266K |
| 70486 | <1% | 2,207 | $252K | |
| 93970 | <1% | 1,305 | $247K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 392 | $213K |
| 73610 | <1% | 3,113 | $197K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,073 | $194K |
| 74174 | <1% | 279 | $187K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,550 | $186K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,447 | $186K |
| 80053 | Comprehensive metabolic panel | <1% | 89,567 | $175K |
| 70496 | <1% | 2,230 | $168K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 140 | $168K |
| 73562 | <1% | 2,720 | $163K | |
| 73630 | <1% | 3,688 | $154K | |
| 73130 | <1% | 3,001 | $137K | |
| 99201 | <1% | 1,252 | $130K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,581 | $124K |
| 93971 | <1% | 2,855 | $118K | |
| 12011 | <1% | 745 | $102K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,263 | $96K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,132 | $91K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20,591 | $91K |
| 81513 | <1% | 389 | $90K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,777 | $75K |
| 12002 | <1% | 545 | $74K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,612 | $67K |
| 10060 | <1% | 567 | $63K | |
| 84702 | <1% | 5,810 | $57K | |
| 70491 | <1% | 128 | $50K | |
| 97597 | <1% | 1,418 | $46K | |
| 58558 | <1% | 29 | $45K | |
| 73110 | <1% | 2,178 | $44K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,033 | $42K |
| 59025 | Fetal non-stress test | <1% | 10,621 | $41K |
| 73564 | <1% | 533 | $40K | |
| 49083 | <1% | 144 | $38K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 229 | $35K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 556 | $34K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,399 | $33K |
| 36430 | <1% | 547 | $33K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,180 | $31K |
| 75574 | <1% | 488 | $30K | |
| 87070 | <1% | 2,029 | $29K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 44,857 | $28K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,363 | $28K |
| 72141 | <1% | 159 | $27K | |
| 72128 | <1% | 1,831 | $26K | |
| 73030 | <1% | 2,628 | $25K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,773 | $25K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 38,895 | $24K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,813 | $22K |
| 29125 | <1% | 278 | $22K | |
| 97162 | <1% | 3,056 | $20K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,222 | $20K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,399 | $19K |
| 74018 | <1% | 1,089 | $19K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,837 | $18K |
| 73140 | <1% | 846 | $17K | |
| 86923 | <1% | 247 | $16K | |
| J3490 | Unclassified drugs | <1% | 67,882 | $16K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,243 | $16K |
| 87507 | <1% | 166 | $15K | |
| 86635 | <1% | 667 | $14K | |
| 71250 | <1% | 533 | $13K | |
| 93976 | <1% | 6,809 | $12K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 761 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,324 | $12K |
| 88307 | <1% | 808 | $12K | |
| C1769 | Guide wire | <1% | 2,976 | $11K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,032 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 97,133 | $11K |
| 73502 | <1% | 504 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,970 | $10K |
| 73080 | <1% | 1,074 | $10K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,804 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 45,578 | $9K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,195 | $9K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,183 | $9K |
| 96376 | <1% | 13,187 | $9K | |
| 73090 | <1% | 1,250 | $9K | |
| 88304 | <1% | 1,481 | $9K | |
| 70544 | <1% | 45 | $9K | |
| S9083 | Global fee urgent care centers | <1% | 543 | $8K |
| 83690 | <1% | 29,980 | $8K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 592 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 27,772 | $7K |
| 84703 | <1% | 24,346 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 36 | $6K |
| 29515 | <1% | 40 | $6K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 28 | $6K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 96 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 16,229 | $5K |
| 93798 | <1% | 81 | $5K | |
| 97166 | <1% | 2,030 | $5K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 208 | $5K |
| 82248 | <1% | 1,062 | $5K | |
| 81025 | <1% | 14,401 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,834 | $5K |
| 81001 | <1% | 37,040 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,658 | $5K |
| 84484 | <1% | 30,584 | $5K | |
| 87186 | <1% | 4,805 | $4K | |
| 97161 | <1% | 1,252 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,360 | $4K |
| 86308 | <1% | 572 | $4K | |
| 87040 | <1% | 7,225 | $4K | |
| 73590 | <1% | 1,482 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 177 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 302 | $3K |
| 74019 | <1% | 80 | $3K | |
| 73552 | <1% | 375 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 107,060 | $3K |
| C1729 | Catheter, drainage | <1% | 846 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,514 | $3K |
| 90715 | <1% | 2,835 | $2K | |
| 76801 | <1% | 2,315 | $2K | |
| 97163 | <1% | 642 | $2K | |
| 83735 | <1% | 26,154 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 26 | $2K |
| 72100 | <1% | 326 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,935 | $2K |
| 72040 | <1% | 88 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,560 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 35,781 | $2K |
| 85379 | <1% | 5,936 | $2K | |
| 83605 | <1% | 14,340 | $2K | |
| C8923 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography | <1% | 19 | $2K |
| 69209 | <1% | 181 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 7,520 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,020 | $1K |
| 83880 | <1% | 7,008 | $1K | |
| 92523 | <1% | 64 | $1K | |
| 85610 | <1% | 24,914 | $1K | |
| 76870 | <1% | 57 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,842 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,966 | $1K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,175 | $1K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 54 | $1K |
| 81003 | <1% | 25,460 | $1K | |
| 85730 | <1% | 18,701 | $1K | |
| 80061 | Lipid panel | <1% | 3,696 | $999.33 |
| 92610 | <1% | 207 | $991.69 | |
| 87634 | <1% | 2,109 | $962.26 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,712 | $912.62 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 130 | $900.00 |
| 86141 | <1% | 2,979 | $899.44 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,169 | $882.87 |
| 76770 | <1% | 186 | $875.70 | |
| 82550 | <1% | 6,626 | $825.73 | |
| 82962 | <1% | 29,235 | $798.47 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,774 | $797.09 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,820 | $779.13 |
| 86850 | <1% | 7,735 | $756.04 | |
| 73060 | <1% | 176 | $747.29 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,670 | $682.30 |
| A9270 | Non-covered item or service | <1% | 25,987 | $655.31 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 19,327 | $632.83 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 74 | $623.35 |
| 97167 | <1% | 484 | $621.11 | |
| 82565 | <1% | 2,118 | $581.67 | |
| 85027 | <1% | 10,469 | $558.88 | |
| 87081 | <1% | 48 | $518.16 | |
| 82803 | <1% | 1,821 | $493.39 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,398 | $491.58 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,859 | $470.05 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,757 | $456.64 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,937 | $449.90 |
| 86900 | <1% | 8,726 | $446.92 | |
| 87205 | <1% | 2,290 | $434.94 | |
| 87210 | <1% | 880 | $413.70 | |
| 86901 | <1% | 8,728 | $407.81 | |
| 97802 | <1% | 12 | $380.65 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,740 | $376.42 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,673 | $375.11 |
| 85652 | <1% | 2,402 | $345.81 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 187 | $304.83 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,906 | $303.95 |
| 84100 | <1% | 5,959 | $296.02 | |
| 82607 | <1% | 1,304 | $282.05 | |
| 72192 | <1% | 14 | $267.50 | |
| 87077 | <1% | 5,833 | $267.31 | |
| 84439 | <1% | 1,110 | $257.21 | |
| 87480 | <1% | 387 | $236.39 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 623 | $225.35 |
| 84550 | <1% | 1,835 | $225.27 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,962 | $223.12 |
| 72170 | <1% | 989 | $221.21 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 44 | $210.32 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 45 | $208.74 |
| 97165 | <1% | 98 | $204.31 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,331 | $201.68 |
| 82728 | <1% | 1,158 | $196.02 | |
| 99152 | <1% | 2,456 | $186.71 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 400 | $183.30 |
| 82140 | <1% | 1,359 | $182.37 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 33 | $181.70 |
| 86592 | <1% | 580 | $176.82 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,666 | $165.45 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,655 | $140.80 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,037 | $130.85 |
| 84145 | <1% | 2,113 | $120.17 | |
| 82746 | <1% | 1,071 | $116.70 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,413 | $115.04 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,563 | $113.01 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,533 | $102.35 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,450 | $102.28 |
| 87428 | <1% | 313 | $102.26 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,076 | $101.10 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,725 | $100.63 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 193 | $90.00 |
| 84466 | <1% | 783 | $84.48 | |
| 84156 | <1% | 1,843 | $81.07 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 44 | $80.36 |
| 87420 | <1% | 117 | $78.65 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,983 | $76.86 |
| 85007 | <1% | 3,882 | $69.06 | |
| 84270 | <1% | 33 | $66.81 | |
| 85049 | <1% | 518 | $65.54 | |
| 88342 | <1% | 634 | $63.61 | |
| 87510 | <1% | 387 | $61.92 | |
| 87660 | <1% | 387 | $61.82 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 440 | $59.54 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,954 | $55.83 |
| 83540 | <1% | 890 | $51.12 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,597 | $48.60 |
| 82731 | <1% | 221 | $45.26 | |
| 87400 | <1% | 757 | $42.67 | |
| 87147 | <1% | 415 | $34.28 | |
| 82010 | <1% | 753 | $32.99 | |
| 96367 | <1% | 294 | $31.05 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,681 | $29.15 |
| 85014 | <1% | 857 | $29.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,726 | $24.57 |
| 83615 | <1% | 1,736 | $21.68 | |
| 82570 | <1% | 1,841 | $19.95 | |
| 84132 | <1% | 1,407 | $19.89 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,161 | $19.21 |
| 82150 | <1% | 575 | $17.68 | |
| 85384 | <1% | 1,749 | $16.60 | |
| 36591 | <1% | 21 | $12.71 | |
| Q0114 | Fern test | <1% | 1,027 | $11.51 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 151 | $11.21 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,919 | $9.36 |
| 87340 | <1% | 198 | $9.12 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,101 | $9.07 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 482 | $9.00 |
| 81005 | <1% | 693 | $7.03 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 229 | $6.65 |
| 85018 | <1% | 582 | $1.86 | |
| 85347 | <1% | 576 | $1.72 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 434 | $1.52 |
| 84520 | 0% | 1,380 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 2,482 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 242 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 80 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 15 | $0.00 |
| 87075 | 0% | 393 | $0.00 | |
| 87481 | 0% | 382 | $0.00 | |
| 89051 | 0% | 186 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 121 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 530 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 76 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 143 | $0.00 |
| 82947 | 0% | 126 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 94 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 787 | $0.00 |
| 90661 | 0% | 77 | $0.00 | |
| 85045 | 0% | 48 | $0.00 | |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 267 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 93 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 14 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 83 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 529 | $0.00 |
| 93880 | 0% | 14 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 79 | $0.00 |
| 88302 | 0% | 12 | $0.00 | |
| 87149 | 0% | 22 | $0.00 | |
| 87324 | 0% | 14 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 19 | $0.00 |
| 82247 | 0% | 19 | $0.00 | |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 25 | $0.00 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 24 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 23 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 327 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 544 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,422 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 288 | $0.00 |
| 82553 | 0% | 14 | $0.00 | |
| 90686 | 0% | 812 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 127 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 236 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 34 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 436 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 139 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 435 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 390 | $0.00 |
| 86706 | 0% | 104 | $0.00 | |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 222 | $0.00 |
| 87449 | 0% | 40 | $0.00 | |
| 87493 | 0% | 12 | $0.00 | |
| 80051 | 0% | 139 | $0.00 | |
| 51798 | 0% | 13 | $0.00 | |
| 85576 | 0% | 47 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 83 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 78 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 89 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| 82945 | 0% | 16 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 55 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 51 | $0.00 |
| 90732 | 0% | 42 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 32 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 13 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 14 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 14 | $0.00 |
| 96368 | 0% | 24 | $0.00 | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 0% | 13 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 14 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 21 | $0.00 |
| 84157 | 0% | 15 | $0.00 | |
| 88341 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSORENSON, ERIC (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY COMMUNITY CARE